DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Tamura K, Tsurutani J, Takahashi S. et al.
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Lancet Oncol 2019;
20: 816-826
We do not assume any responsibility for the contents of the web pages of other providers.